The efficacy and safety of milnacipran for treatment of fibromyalgia. A randomized, double-blind, placebo-controlled trial

Journal of Rheumatology

Volumn 36, Issue 2, 2009, Pages 398-409

  Mease, Philip J ^a   Clauw, Daniel J ^b   Gendreau, R Michael ^c   Rao, Srinivas G ^c   Kranzler, Jay ^c   Chen, Wei ^d   Palmer, Robert H ^d  

^a Seattle Rhumatology Associates   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c Cypress Bioscience Inc   (United States)

^d FOREST RESEARCH INSTITUTE   (United States)

Author keywords

Fatigue; Fibromyalgia; Milnacipran; Pain; Physical function; Rheumatology

Indexed keywords

MILNACIPRAN; PLACEBO; ADRENERGIC RECEPTOR AFFECTING AGENT; CYCLOPROPANE DERIVATIVE; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; CLINICAL TRIAL; COGNITION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FIBROMYALGIA; HEADACHE; HEART PALPITATION; HEART RATE; HOT FLUSH; HUMAN; HYPERHIDROSIS; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PAIN; PATIENT SATISFACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROTONIN UPTAKE; SHORT FORM 36; SIDE EFFECT; SINUSITIS; TREATMENT DURATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VISUAL ANALOG SCALE; WEIGHT REDUCTION; XEROSTOMIA; CHEMICALLY INDUCED DISORDER; CHRONIC FATIGUE SYNDROME; COGNITIVE DEFECT; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECT; MIDDLE AGED; PAIN ASSESSMENT; PATHOPHYSIOLOGY; SKELETAL MUSCLE; TREATMENT OUTCOME;

ADRENERGIC UPTAKE INHIBITORS; ADULT; COGNITION DISORDERS; CYCLOPROPANES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FATIGUE SYNDROME, CHRONIC; FEMALE; FIBROMYALGIA; HEADACHE; HUMANS; MALE; MIDDLE AGED; MUSCLE, SKELETAL; NAUSEA; PAIN MEASUREMENT; PLACEBOS; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 64849117499     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.080734     Document Type: Article

References (58)

1. Hudson JI, Pope HG Jr. The relationship between fibromyalgia and major depressive disorder. Rheum Dis Clin North Am 1996;22:285-303. (Pubitemid 26149680)
2. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990;33:160-172
3. Mease P. Fibromyalgia syndrome: review of clinical presentation, pathogenesis, outcome measures, and treatment. J Rheumatol 2005;32 Suppl 75:6-21. (Pubitemid 41113954)
4. Baker K, Barkhuizen A. Pharmacologic treatment of fibromyalgia. Curr Pain Headache Rep 2005;9:301-306 (Pubitemid 41419333)
5. Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995;38:19-28.
6. Clauw DJ, Chrousos GP. Chronic pain and fatigue syndromes: overlapping clinical and neuroendocrine features and potential pathogenic mechanisms. Neuroimmunomodulation 1997;4:134-153 (Pubitemid 28093996)
7. Yunus MB. Towards a model of pathophysiology of fibromyalgia: aberrant central pain mechanisms with peripheral modulation. J Rheumatol 1992;19:846-850
8. Bradley LA, McKendree-Smith NL, Alberts KR, Alarcon GS, Mountz JM, Deutsch G. Use of neuroimaging to understand abnormal pain sensitivity in fibromyalgia. Curr Rheumatol Rep 2000;2:141-148
9. Goldenberg DL, Burckhardt C, Crofford L. Management of fibromyalgia syndrome. JAMA 2004;292:2388-2395 (Pubitemid 39491924)
10. Chu LF, Clark DJ, Angst MS. Opioid tolerance and hyperalgesia in chronic pain patients after one month of oral morphine therapy: a preliminary prospective study. J Pain 2006;7:43-48 (Pubitemid 43097262)
11. Gendreau RM, Thorn MD, Gendreau JF, et al. Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol 2005;32:1975-1985 (Pubitemid 41429029)
12. Clauw DJ, Mease P, Palmer RH, Gendreau RM, Wang Y. Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clin Ther 2008;30:1988-2004.
13. Branco JC, Perrot S, Bragee G, Zacchrisson O, Mikkelsen K, Mainguy Y. Milnacipran for the treatment of fibromyalgia syndrome: a European multicenter, randomized, double-blind, placebo-controlled trial [abstract]. Ann Rheum Dis 2008;67 Suppl II:251.
14. Vaishnavi SN, Nemeroff CB, Plott SJ, Rao SG, Kranzler J, Owens MJ. Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. Biol Psychiatry 2004;55:320-322 (Pubitemid 38117171)
15. Dubner R, Hargreaves KM. The neurobiology of pain and its modulation. Clin J Pain 1989;5 Suppl 2:S1-4. (Pubitemid 20021673)
16. Jones CK, Eastwood BJ, Need AB, Shannon HE. Analgesic effects of serotonergic, noradrenergic or dual reuptake inhibitors in the carrageenan test in rats: evidence for synergism between serotonergic and noradrenergic reuptake inhibition. Neuropharmacology 2006;51:1172-1180 (Pubitemid 44715970)
17. Mochizucki D. Serotonin and noradrenaline reuptake inhibitors in animal models of pain. Hum Psychopharmacol 2004;19 Suppl 1:S15-9.
18. Russell IJ, Vaeroy H, Javors M, Nyberg F. Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum 1992;35:550-556
19. Stahl SM. The psychopharmacology of energy and fatigue. J Clin Psychiatry 2002;63:7-8. (Pubitemid 34113479)
20. Stahl SM. Neurotransmission of cognition, part 1, Dopamine is a hitchhiker in frontal cortex: norepinephrine transporters regulate dopamine. J Clin Psychiatry 2003;64:4-5. (Pubitemid 36182221)
21. Moret C, Charveron M, Finberg JP, Couzinier JP, Briley M. Biochemical profile of midalcipran (F 2207), 1-phenyl-1-diethyl-aminocarbonyl-2-aminomethyl- cyclopropane (Z) hydrochloride, a potential fourth generation antidepressant drug. Neuropharmacology 1985;24:1211-1219
22. Max MB, Lynch SA, Muir J, Shoaf SE, Smoller B, Dubner R. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 1992;326:1250-1256
23. Atkinson JH, Slater MA, Capparelli EV, et al. Efficacy of noradrenergic and serotonergic antidepressants in chronic back pain: a preliminary concentration-controlled trial. J Clin Psychopharmacol 2007;27:135-142 (Pubitemid 46594928)
24. Atkinson JH, Slater MA, Wahlgren DR, et al. Effects of noradrenergic and serotonergic antidepressants on chronic low back pain intensity. Pain 1999;83:137-145 (Pubitemid 29479271)
25. Lecrubier Y. Milnacipran: the clinical properties of a selective serotonin and noradrenaline reuptake inhibitor. Hum Psychopharmacol 1997;12:S127-S34.
26. Puozzo C, Lens S, Reh C, et al. Lack of interaction of milnacipran with the cytochrome P450 isoenzymes frequently involved in the metabolism of antidepressants. Clin Pharmacokinet 2005;44:977-988 (Pubitemid 41252846)
27. Vitton O, Gendreau M, Gendreau J, Kranzler J, Rao SG. A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Hum Psychopharmacol 2004;19 Suppl 1:S27-35.
28. Nagaoka S, Ohno M, Sekiguchi A. An open-label clinical trial of milnacipran in fibromyalgia syndrome with co-morbid depressive symptoms. Int J Psychiatry Clin Pract 2004;8:47-51. (Pubitemid 38332459)
29. Kamata M, Takahashi H, Naito S, Higuchi H. Effectiveness of milnacipran for the treatment of chronic pain: a case series. Clin Neuropharmacol 2004;27:208-210 (Pubitemid 39447215)
30. Briley M. Clinical experience with dual action antidepressants in different chronic pain syndromes. Hum Psychopharmacol 2004;19 Suppl 1:S21-5.
31. Kito S, Nakajima T, Koga Y. Milnacipran for the drastic improvement of refractory pain in a patient without depressive symptoms: a case report. Eur Psychiatry 2005;20:355. (Pubitemid 40978564)
32. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini- International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59 Suppl 20:22-33. (Pubitemid 29001829)
33. Ware JE, Kosinski M, Keller SK. SF-36 physical and mental health summary scales: a user's manual. Boston: The Health Institute; 1994.
34. Burckhardt CS, Clark SR, Bennett RM. The Fibromyalgia Impact Questionnaire: development and validation. J Rheumatol 1991;18:728-733
35. Smets EM, Garssen B, Bonke B, De Haes JC. The Multidimensional Fatigue Inventory (MFI): psychometric qualities of an instrument to assess fatigue. J Psychosom Res 1995;39:315-325
36. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561-571
37. Hays RD. Sleep measures. Durham, NC: University Press; 1992.
38. Hays RD, Martin SA, Sesti AM, Spritzer KL. Psychometric properties of the Medical Outcomes Study sleep measure. Sleep Med 2005;6:41-44
39. Pincus T, Swearingen C, Wolfe F. Toward a multidimensional Health Assessment Questionnaire (MDHAQ): assessment of advanced activities of daily living and psychological status in the patient-friendly health assessment questionnaire format. Arthritis Rheum 1999;42:2220-2230 (Pubitemid 30263609)
40. Seidenberg M, Haltiner A, Taylor MA, Hermann BB, Wyler A. Development and validation of a Multiple Ability Self-Report Questionnaire. J Clin Exp Neuropsychol 1994;16:93-104. (Pubitemid 24051080)
41. McGahuey CA, Gelenberg AJ, Laukes CA, et al. The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther 2000;26:25-40. (Pubitemid 30046590)
42. Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11- point numerical pain rating scale. Pain 2001;94:149-158 (Pubitemid 33016608)
43. Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 2008;9:105-121
44. Thumboo J, Fong KY, Chan SP, et al. A prospective study of factors affecting quality of life in systemic lupus erythematosus. J Rheumatol 2000;27:1414-1420 (Pubitemid 30354037)
45. Beaton DE, Boers M, Wells GA. Many faces of the minimal clinically important difference: a literature review and directions for future research. Curr Opin Rheumatol 2002;14:109-114 (Pubitemid 34185291)
46. Strand V, Scott DL, Emery P, et al. Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis. J Rheumatol 2005;32:590-601. (Pubitemid 40524689)
47. Strand V. Longer term benefits of treating rheumatoid arthritis: assessment of radiographic damage and physical function in clinical trials. Clin Exp Rheumatol 2004;22:S57-64. (Pubitemid 39328356)
48. Angst F, Aeschlimann A, Stucki G. Smallest detectable and minimal clinically important differences of rehabilitation intervention with their implications for required sample sizes using WOMAC and SF-36 quality of life measurement instruments in patients with osteoarthritis of the lower extremities. Arthritis Rheum 2001;45:384-391 (Pubitemid 32738745)
49. Strand V, Kelman A. Outcome measures in osteoarthritis: randomized controlled trials. Curr Rheumatol Rep 2004;6:20-30.
50. Stucki G, Ewert T. How to assess the impact of arthritis on the individual patient: the WHO ICF. Ann Rheum Dis 2005;64:664-668 (Pubitemid 40559290)
51. Mease P, Arnold LM, Bennett R, et al. Fibromyalgia syndrome. J Rheumatol 2007;34:1415-1425 (Pubitemid 46898129)
52. Arnold LM, Rosen A, Pritchett YL, et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005;119:5-15. (Pubitemid 41752960)
53. Russell IJ, Mease PJ, Smith TR, et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain 2008;136:432-444
54. Stahl SM, Grady MM, Moret C, Briley M. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr 2005;10:732-747 (Pubitemid 41443048)
55. Epstein SA, Kay G, Clauw D, et al. Psychiatric disorders in patients with fibromyalgia. A multicenter investigation. Psychosomatics 1999;40:57-63.
56. Arnold LM, Russell IJ, Diri EW, et al. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain 2008;9:792-805.
57. Mease PJ, Russell IJ, Arnold LM, et al. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol 2008;35:502-514
58. Goldenberg D, Clauw DJ, Palmer RH, Gendreau RM. One-year durability of response to milnacipran treatment for fibromyalgia [abstract]. Arthritis Rheum 2007;56 Suppl:S603.